Melanotan II (MT-II) is a synthetic cyclic heptapeptide (Ac-Nle4-c[Asp5, D-Phe7, Lys10]-α-MSH-(4-10)-NH2) developed at the University of Arizona as a potent, non-selective agonist at melanocortin receptors. It was originally synthesised as a potential photoprotective agent, the hypothesis being that inducing melanin production could protect the skin against UV-induced DNA damage without requiring UV exposure itself. Subsequent research revealed a broader and more complex pharmacological profile involving multiple melanocortin receptor subtypes, including central effects on sexual function, appetite regulation, and cardiovascular tone. Melanotan II remains an active research tool for studying the melanocortin system in its entirety.
Melanocortin Receptor Subtypes: MC1R through MC5R
The melanocortin receptor family comprises five G-protein coupled receptor subtypes (MC1R–MC5R), each with distinct tissue distribution and physiological functions. All five are coupled to Gs proteins, activating adenylyl cyclase and elevating intracellular cAMP upon agonist binding. Melanotan II is a non-selective agonist with high affinity across MC1R, MC3R, MC4R, and MC5R, with particularly potent activity at MC1R (the melanogenesis receptor) and MC4R (the hypothalamic satiety and sexual arousal receptor).
MC1R is expressed primarily on cutaneous melanocytes and governs the switch between eumelanin (brown/black pigment) and phaeomelanin (red/yellow pigment) production. Gs-coupled cAMP elevation via MC1R activates MITF (microphthalmia-associated transcription factor), upregulating tyrosinase, TRP-1, and TRP-2, the key enzymes in the eumelanin synthesis pathway. This is the primary mechanism underlying Melanotan II’s tanning effects in preclinical models.
MC3R and MC4R are expressed centrally, with MC3R in the hypothalamic arcuate nucleus playing a role in energy homeostasis, and MC4R in the paraventricular nucleus mediating satiety signalling and sexual arousal modulation. The overlap between Melanotan II’s MC4R activity and PT-141’s mechanism (see PT-141 Research Review) explains the sexual arousal effects observed in early Melanotan II human trials. MC5R is expressed in exocrine glands, skin, and skeletal muscle, with emerging research suggesting roles in sebaceous gland function and immune modulation. Stackpure offers Melanotan II peptide vial for qualified in vitro and preclinical research.
Melanogenesis Pathway: From cAMP to Melanin
The molecular pathway from MC1R activation to melanin production is well characterised. MC1R-coupled Gs activation elevates intracellular cAMP, which activates protein kinase A (PKA). PKA phosphorylates CREB (cAMP response element-binding protein), driving transcription of MITF, the master regulator of melanocyte identity and melanin synthesis gene expression. MITF transactivates the promoters of tyrosinase (TYR), TYRP1, and TYRP2 (DCT), the three key enzymes that catalyse sequential steps in eumelanin biosynthesis from tyrosine substrate.
Eumelanin synthesis proceeds via the DOPA pathway: tyrosinase oxidises tyrosine to DOPA and DOPA to dopaquinone, which undergoes non-enzymatic cyclisation to form leucodopachrome and subsequently, via TRP-2/TYRP1-catalysed reactions, 5,6-dihydroxyindole-2-carboxylic acid (DHICA) polymers constituting mature eumelanin. Melanotan II activates this entire cascade with substantially greater potency and duration than the endogenous ligand α-MSH, due to its resistance to enzymatic degradation and the cyclisation/Nle4/D-Phe7 modifications that optimise receptor binding geometry.
Central Melanocortin Effects: Appetite, Arousal, and Cardiovascular Research
Melanotan II’s non-selective activity across MC3R, MC4R, and MC5R produces several centrally-mediated effects that are of independent research interest. MC4R activation in the paraventricular nucleus suppresses food intake via modulation of neuropeptide Y (NPY) and agouti-related peptide (AgRP) signalling, making Melanotan II a research tool for studying hypothalamic appetite circuits. Studies in obese rodent models have demonstrated significant reductions in caloric intake and body weight with MT-II administration, effects that cannot be attributed to MC1R activation since peripheral melanocytes do not regulate feeding behaviour.
MC4R activation also engages the dopaminergic arousal pathway described in the PT-141 review, the early clinical trial experience with intranasal Melanotan II in human subjects (Wessells et al., 2000, Journal of Urology) provided the first evidence that melanocortin agonists could produce erectile responses in men, a finding that led to the PT-141 development programme. These effects make Melanotan II relevant to researchers studying the intersection of photoprotection, appetite regulation, and sexual function within the unified melanocortin system framework.
Photoprotective Research Applications
The original hypothesis motivating Melanotan II’s development, that pharmacological induction of eumelanin could protect against UV-induced carcinogenesis, remains scientifically valid but operationally complex. Eumelanin is a highly effective broad-spectrum UV absorber and quencher of reactive oxygen species generated by UV exposure. Studies in murine models demonstrated that MC1R-agonist-induced pigmentation reduced UV-induced cyclobutane pyrimidine dimer (CPD) formation, a primary mechanism of UV-induced DNA mutation.
More recent research has examined whether MC1R activation provides photoprotective signalling beyond pigmentation alone, specifically, whether cAMP elevation and MITF activation drive DNA repair gene upregulation that is partially independent of melanin production. Work by D’Orazio et al. (2006, Nature) demonstrated that MC1R signalling in melanocytes upregulates nucleotide excision repair (NER) capacity, the primary repair pathway for bulky UV-induced DNA adducts, suggesting a direct genome protection role beyond UV shielding by melanin. This finding is mechanistically significant for cancer biology researchers studying the role of MC1R variants (which are common in fair-skinned populations) in UV sensitivity and melanoma risk.
Comparison with Afamelanotide (Scenesse)
Afamelanotide (formerly CUV1647) is the most clinically advanced MC1R agonist, approved in the EU and US for erythropoietic protoporphyria (EPP) under the brand name Scenesse. As an α-MSH analogue incorporating the same Nle4 modification as Melanotan II but lacking the D-Phe7 and cyclisation modifications, Afamelanotide is a more selective MC1R agonist with reduced affinity at MC3R and MC4R. This selective profile reduces the central sexual arousal and appetite-suppressive effects while retaining potent melanogenesis stimulation, a pharmacological refinement driven by clinical development requirements that is mechanistically instructive for receptor subtype contribution research. Comparing Melanotan II and Afamelanotide effects at each receptor subtype provides a useful approach for isolating MC3R/MC4R contributions to observed outcomes.
Frequently Asked Questions
Is Melanotan II the same as Melanotan I?
No. Melanotan I (Afamelanotide) is a linear α-MSH analogue incorporating an Nle4 substitution but lacking the D-Phe7 modification and cyclisation of Melanotan II. Melanotan II is a cyclic heptapeptide with higher potency, greater receptor non-selectivity (including significant MC4R activity), and different pharmacokinetic characteristics. Melanotan I (Afamelanotide) is the compound that received EU/US clinical approval for EPP.
What is the significance of the D-Phe7 modification in Melanotan II?
The D-Phe7 (D-phenylalanine at position 7) modification substantially increases receptor binding affinity by optimising the peptide’s three-dimensional binding conformation at melanocortin receptor binding pockets. The unnatural D-amino acid also confers protease resistance, extending the peptide’s biological half-life compared to the native α-MSH sequence. These modifications are the primary drivers of Melanotan II’s substantially greater potency compared to α-MSH.
What purity standard does Stackpure apply to Melanotan II?
Stackpure’s Melanotan II is produced to +99% purity as verified by HPLC analysis with mass spectrometry confirmation. Batch-specific Certificates of Analysis are available through Stackpure’s Lab Testing page.